Tuesday, August 18, 2026
ExploreSearch
Finance Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,812
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,812 facts checked against source5,219 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 13, 2026

PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript

View original at finance.yahoo.com
“PDS Biotechnology reported a net loss of $7.3 million for Q1 2026, an improvement from $8.5 million in Q1 2025... Mr. Bozgaard will review the financial results for the quarter ended March 31, 2026.”
Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • PDS Biotechnology reported a net loss of $7.3 million for Q1 2026

    60% confidence

  • Positive results from PDS01 ADC trials in prostate and colorectal cancer support its potential across multiple solid tumor types

    60% confidence

  • New patents for PDS0101 in the US and Japan extend market protection into the 2040s

    60% confidence

  • Q1 2026 net loss of $7.3 million represents an improvement from the $8.5 million net loss in Q1 2025

    60% confidence

  • During this call, forward-looking statements are being made which are subject to various risks and uncertainties that could cause actual results to differ materially

    60% confidence

  • Management is focusing on advancing PDS0101 as a treatment for HPV 16 positive cancers, with late-stage trials in collaboration with key institutions

    60% confidence

  • The year-over-year improvement in net loss was driven by reduced research and development and general administrative expenses

    60% confidence

  • The amendment of the VERSATILE-003 trial to include progression-free survival as a primary endpoint potentially reduces trial duration and costs

    60% confidence

Cited in these Via News reports